Juvenile Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012;64(12):1787-1793. doi:10.1002/acr.21757

García-Carrasco M, Mendoza Pinto C, Jiménez Hernández C, et al. Antiphospholipid syndrome. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 26. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459442/

Charras A, Smith E, Hedrich CM. Systemic Lupus Erythematosus in Children and Young People. Curr Rheumatol Rep. 2021;23(3):20. Published 2021 Feb 10. doi:10.1007/s11926-021-00985-0

Levy DM. childhood-onset systemic lupus erythematosus (SLE): clinical manifestations and diagnosis. In: upToDate, Klein-gitelman M (Ed.), (Access: Haziran 2023).

Vilar MJ, Sato EI. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus. 2002;11(8):528-532. doi:10.1191/0961203302lu244xx

Ramírez Gómez LA, Uribe Uribe O, Osio Uribe O, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus. 2008;17(6):596-604. doi:10.1177/0961203307088006

Klein-Gitelman MS, Beresford MW. Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, and Undifferentiated Connective Tissue Disease. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn L,Mellins ED, Fuhlbrigge RC (eds). Textbook of Pediatric Rheumatology (8th ed). Philadelphia: Elsevier, 2021: 295–329.

Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi:10.1016/j.clim.2019.108274

Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J. 2012;10(1):21. Published 2012 Aug 10. doi:10.1186/1546-0096-10-21

Radanova M, Vasilev V, Deliyska B, Kishore U, Ikonomov V, Ivanova D. Anti-C1q autoantibodies specific against the globular domain of the C1qB-chain from patient with lupus nephritis inhibit C1q binding to IgG and CRP. Immunobiology. 2012;217(7):684-691. doi:10.1016/j.imbio.2011.11.007

Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174-194. doi:10.1016/j.autrev.2012.08.018

Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011;13(6):250. doi:10.1186/ar3528

Sato N, Ohsawa I, Nagamachi S, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis [published correction appears in Lupus. 2011 Nov;20(13):1455]. Lupus. 2011;20(13):1378-1386. doi:10.1177/0961203311415561

Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2390-2401. doi:10.1002/art.24634

Midgley A, Beresford MW. Cellular localization of nuclear antigen during neutrophil apoptosis: mechanism for autoantigen exposure?. Lupus. 2011;20(6):641-646. doi:10.1177/0961203310392421

Caielli S, Banchereau J, Pascual V. Neutrophils come of age in chronic inflammation. Curr Opin Immunol. 2012;24(6):671-677. doi:10.1016/j.coi.2012.09.008

Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20. doi:10.1126/scitranslmed.3001201

Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 1996;85(3):311-318. doi:10.1016/s0092-8674(00)81110-1

Slingsby JH, Norsworthy P, Pearce G, et al. Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum. 1996;39(4):663-670. doi:10.1002/art.1780390419

Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2013;72 Suppl 2(0 2):ii56-ii61. doi:10.1136/annrheumdis-2012-202351

Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) - Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488-504. doi:10.1016/j.berh.2018.02.001

Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20(2):170-179. doi:10.1101/gr.100289.109

Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev. 2010;9(7):494-498. doi:10.1016/j.autrev.2010.02.008

Zandman-Goddard G, Berkun Y, Barzilai O, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci. 2009;1173:658-663. doi:10.1111/j.1749-6632.2009.04754.x

Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus. 2012;21(3):241-250. doi:10.1177/0961203311426568

Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277. doi:10.1002/art.1780251101

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928

Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473

Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819

Fonseca AR, Gaspar-Elsas MI, Land MG, de Oliveira SK. Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology (Oxford). 2015;54(2):241-247. doi:10.1093/rheumatology/keu278

Lopes SRM, Gormezano NWS, Gomes RC, et al. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. Lupus. 2017;26(9):996-1001. doi:10.1177/0961203317690616

Beresford MW, Cleary AG, Sills JA, Couriel J, Davidson JE. Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus. 2005;14(2):152-158. doi:10.1191/0961203305lu2073oa

Azhar AS, Awlia OM, Muzaffer MA. Cardiovascular complications in paediatric-onset systemic lupus erythematosus in Saudi Arabian patients. Clin Exp Rheumatol. 2017;35(3):535-541.

Guevara JP, Clark BJ, Athreya BH. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. J Rheumatol. 2001;28(4):854-859.

Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, et al. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Clin Exp Rheumatol. 2017;35(6):1047-1055.

Chang JC, Xiao R, Mercer-Rosa L, Knight AM, Weiss PF. Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. Lupus. 2018;27(13):2146-2154. doi:10.1177/0961203318804889

Al-Abbad AJ, Cabral DA, Sanatani S, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus. 2001;10(1):32-37. doi:10.1191/096120301669980721

Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr. 1998;132(1):109-116. doi:10.1016/s0022-3476(98)70494-9

Panchal L, Divate S, Vaideeswar P, Pandit SP. Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 patients in India. J Postgrad Med. 2006;52(1):5-10.

Chang JC, Knight AM, Xiao R, Mercer-Rosa LM, Weiss PF. Use of echocardiography at diagnosis and detection of acute cardiac disease in youth with systemic lupus erythematosus. Lupus. 2018;27(8):1348-1357. doi:10.1177/0961203318772022

Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550-556. doi:10.1016/j.jpeds.2007.09.019

Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011;20(6):588-597. doi:10.1177/0961203310393378

Ueki K, Ikeuchi H, Ota F, et al. Extremely high levels of C-reactive protein in patients with acute lupus serositis. Mod Rheumatol. 2002;12(3):267-270. doi:10.3109/s101650200049

Altman C.A, KyleW.B., Tejtel K.S. et al. Inflammatory Noninfectious Cardiovascular Diseases. In: Allen HD, Shaddy RE, Penny DJ, Feltes TF, Cetta F, eds. Moss & Adams’ Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult.

Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686. doi:10.1191/0961203305lu2200oa

Ibrahim AM, Siddique MS. Libman-Sacks Endocarditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 6, 2023.

Roldan CA, Sibbitt WL Jr, Greene ER, Qualls CR, Jung RE. Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy. PLoS One. 2021;16(2):e0247052. Published 2021 Feb 16. doi:10.1371/journal.pone.0247052

Libman E, Sacks B. A Hıtherto Undescrıbed Form Of Valvular And Mural Endocardıtıs. Arch Intern Med (Chic). 1924 ve doi:10.1001/archinte.1924.00110300044002), 33(6):701–737.

Ibrahim AM, Siddique MS. Libman-Sacks Endocarditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing ve May 6, 2023.

Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol. 2009;62(7):584-592. doi:10.1136/jcp.2009.064311

Dey S, Lee KI, Subhan S, et al. Hydroxychloroquine and Cardiotoxicity [published online ahead of print, 2023 Mar 15]. Cardiol Rev. 2023 ve doi:10.1097/CRD.0000000000000547, 10.1097/CRD.0000000000000547.

Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc. 1999 ve 74(3):275–284.

Bartosh SM, Fine RN, Sullivan EK. Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation. 2001;72(5):973-978. doi:10.1097/00007890-200109150-00047

Hiraki LT, Lu B, Alexander SR, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011;63(7):1988-1997. doi:10.1002/art.30350

Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol. 2007;22(1):77-83. doi:10.1007/s00467-006-0296-y

Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319-323. doi:10.1097/MAJ.0b013e31827f4ee3

Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited [published correction appears in J Am Soc Nephrol. 2004 Mar;15(3):835-6]. J Am Soc Nephrol. 2004;15(2):241-250. doi:10.1097/01.asn.0000108969.21691.5d

Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898

Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48-49:14-19. doi:10.1016/j.jaut.2014.01.021

Chiewchengchol D, Murphy R, Edwards SW, Beresford MW. Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature. Pediatr Rheumatol Online J. 2015;13:1. Published 2015 Jan 5. doi:10.1186/1546-0096-13-1

Martin L, Chalmers IM. Photosensitivity to fluorescent light in a patient with systemic lupus erythematosus. J Rheumatol. 1983;10(5):811-812.

Ingegnoli F, Zeni S, Meani L, Soldi A, Lurati A, Fantini F. Evaluation of nailfold videocapillaroscopic abnormalities in patients with systemic lupus erythematosus. J Clin Rheumatol. 2005;11(6):295-298. doi:10.1097/01.rhu.0000191193.93720.95

Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am. 2005;52(2):443-vi. doi:10.1016/j.pcl.2005.01.010

Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013;12(7):784-791. doi:10.1016/j.autrev.2013.02.001

Malattia C, Martini A. Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):351-362. doi:10.1016/j.berh.2013.07.007

Gokce M, Bilginer Y, Besbas N, et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012;21(8):878-884. doi:10.1177/0961203312443721

Schmugge M, Revel-Vilk S, Hiraki L, Rand ML, Blanchette VS, Silverman ED. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr. 2003;143(5):666-669. doi:10.1067/S0022-3476(03)00389-5

Yüksel S, Işık Gönül İ, Canpolat N, et al. Renal Biopsy Prognostic Findings in Children With Atypical Hemolytic Uremic Syndrome. Pediatr Dev Pathol. 2020;23(5):362-371. doi:10.1177/1093526620925947

Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008;23(10):1761-1767. doi:10.1007/s00467-007-0616-x

Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr. 2009;155(2):260-265. doi:10.1016/j.jpeds.2009.02.033

Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child. 1997;77(4):299-304. doi:10.1136/adc.77.4.299

Binder E, Edelbauer M. Use of biomarkers in the management of children with lupus. Curr Rheumatol Rep. 2013;15(3):312. doi:10.1007/s11926-012-0312-0

Tekin ZE, Yener GO, Yüksel S. Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. Rheumatol Int. 2018;38(8):1577-1584. doi:10.1007/s00296-018-4088-z

Novak GV, Marques M, Balbi V, et al. Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun Rev. 2017;16(2):132-135. doi:10.1016/j.autrev.2016.12.004

Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol. 1999;11(5):384-392. doi:10.1097/00002281-199909000-00010

Descloux E, Durieu I, Cochat P, et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford). 2008;47(2):183-187. doi:10.1093/rheumatology/kem335

Seaman DE, Londino AV Jr, Kwoh CK, Medsger TA Jr, Manzi S. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics. 1995;96(6):1040-1045.

van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi:10.1136/annrheumdis-2013-205139

Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195-205. doi:10.1136/ard.2007.070367

Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus. 2008;17(2):91-92. doi:10.1177/0961203307086267

Abu-Shakra M. Safety of vaccination of patients with systemic lupus erythematosus. Lupus. 2009;18(13):1205-1208. doi:10.1177/0961203309346507

Appenzeller S, Pineau CA, Clarke AE. Acute lupus myocarditis: Clinical features and outcome. Lupus. 2011;20(9):981-988. doi:10.1177/0961203310395800

Zawadowski GM, Klarich KW, Moder KG, Edwards WD, Cooper LT Jr. A contemporary case series of lupus myocarditis. Lupus. 2012;21(13):1378-1384. doi:10.1177/0961203312456752

Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus [published correction appears in N Engl J Med. 2006 Oct 19;355(16):1746]. N Engl J Med. 2003;349(25):2399-2406. doi:10.1056/NEJMoa035471

Hersh AO, von Scheven E, Yazdany J, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61(1):13-20. doi:10.1002/art.24091

Giordano P, Tesse R, Lassandro G, et al. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. Blood Transfus. 2012;10(3):296-301. doi:10.2450/2011.0069-11

Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(4):27. doi:10.1007/s11926-015-0504-5

Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheum 1999 ve 42:1309.

Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x

Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927-930. doi:10.1136/ard.2006.067314

Swadźba J, Iwaniec T, Szczeklik A, Musiał J. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost. 2007;5(9):1883-1889. doi:10.1111/j.1538-7836.2007.02669.x

Solano C, Lamuño M, Vargas A, Amezcua-Guerra LM. Comparison of the 1999 Sapporo and 2006 revised criteria for the classification of the antiphospholipid syndrome. Clin Exp Rheumatol. 2009;27(6):914-919.

Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76(10):1637-1641. doi:10.1136/annrheumdis-2016-211001

Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9(5):A299-A304. doi:10.1016/j.autrev.2009.11.013

Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk?. Curr Rheumatol Rep. 2001;3(4):271-276. doi:10.1007/s11926-001-0030-5

Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998-1005. doi:10.1016/S1474-4422(09)70239-X

Duarte-García A, Pham MM, Crowson CS, et al. The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study [published correction appears in Arthritis Rheumatol. 2020 Apr;72(4):597]. Arthritis Rheumatol. 2019;71(9):1545-1552. doi:10.1002/art.40901

Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100-e1107. doi:10.1542/peds.2008-1209

Bertero MT, Bazzan M, Carignola R, et al. Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. Lupus. 2012;21(7):806-809. doi:10.1177/0961203312446974

García-Carrasco M, Galarza C, Gómez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus. 2007;16(5):366-373. doi:10.1177/0961203307077108

Manco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol. 1995;48(4):240-243. doi:10.1002/ajh.2830480407

Tavil B, Ozyurek E, Gumruk F, Cetin M, Gurgey A. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347-352. doi:10.1097/MBC.0b013e32809cc95a

Amigo MC, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26(2):331-348. doi:10.1016/s0889-857x(05)70141-1

Driest KD, Sturm MS, O'Brien SH, et al. Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus. Lupus. 2016;25(7):749-753. doi:10.1177/0961203316638164

Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost. 2008;34(3):274-281. doi:10.1055/s-0028-1082271

Avčin T, O’Neil KM. Antiphospholipid Syndrome. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn L,Mellins ED, Fuhlbrigge RC (eds). Textbook of Pediatric Rheumatology (8th ed). Philadelphia: Elsevier, 2021: 330–345.

Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322-332. doi:10.1016/j.semarthrit.2005.07.003

Mizumoto H, Maihara T, Hiejima E, et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr. 2006;165(7):484-488. doi:10.1007/s00431-006-0117-0

Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol. 2004;26(5):327-330. doi:10.1097/00043426-200405000-00015

Unal S, Varan A, Yalçin B, Büyükpamukçu M, Gürgey A. Evaluation of thrombotic children with malignancy. Ann Hematol. 2005;84(6):395-399. doi:10.1007/s00277-005-1004-x

De Meis E, Brandão BC, Capella FC, Garcia JA, Gregory SC. Catastrophic antiphospholipid syndrome in cancer patients: an Interaction of clotting, autoimmunity and tumor growth?. Isr Med Assoc J. 2014;16(9):544-547.

de Groot PG, Oosting JD, Derksen RH. Antiphospholipid antibodies: specificity and pathophysiology. Baillieres Clin Haematol. 1993;6(3):691-709. doi:10.1016/s0950-3536(05)80194-5

Derksen RH, de Groot PG. Tests for lupus anticoagulant revisited. Thromb Res. 2004;114(5-6):521-526. doi:10.1016/j.thromres.2004.06.009

Cook MC. B cell biology, apoptosis, and autoantibodies to phospholipids. Thromb Res. 2004;114(5-6):307-319. doi:10.1016/j.thromres.2004.06.037

Myones BL, McCurdy D. The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment. J Rheumatol Suppl. 2000;58:20-28.

López-Pedrera Ch, Buendía P, Aguirre MA, Velasco F, Cuadrado MJ. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus. 2006;15(3):161-166. doi:10.1191/0961203306lu2276rr

Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 2001;27(3):587-602. doi:10.1016/s0889-857x(05)70222-2

Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients [published correction appears in Cell. 2016 Jun 2;165(6):1548-1550]. Cell. 2016;165(3):551-565. doi:10.1016/j.cell.2016.03.008

Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus. 1998;7 Suppl 2:S52-S54. doi:10.1177/096120339800700213

Arıcı ZS, Özen S. Antifosfolipid Sendrom. In: Poyrazoğlu MH, Sözeri B. Çocuk Romatoloji Kitabı (1. baskı). Ankara, Güneş Medical Bookstore, 2018: 149-155.

Wincup C, Ioannou Y. The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. Front Pediatr. 2018;6:362. Published 2018 Nov 27. doi:10.3389/fped.2018.00362

Noda S, Ogura M, Tsutsumi A, et al. Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome. Pediatr Nephrol. 2012;27(4):681-685. doi:10.1007/s00467-011-2085-5

Ramon I, Mathian A, Bachelot A, et al. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab. 2013;98(8):3179-3189. doi:10.1210/jc.2012-4300

Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HM. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 2003;48(3):732-736. doi:10.1002/art.10835

Asherson RA, Cervera R, Shepshelovich D, Shoenfeld Y. Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis? [published correction appears in J Rheumatol. 2006 Aug;33(8):1714]. J Rheumatol. 2006;33(6):1038-1044.

Sakai M, Shirahata A, Akatsuka J, et al. Antiphospholipid antibodies in children with idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 2002; 43:821-7.

Shaharao V, Bartakke S, Muranjan MN, Bavdekar MS, Bavdekar SB, Udani VP. Recurrent acute transverse myelopathy: association with antiphospholipid antibody syndrome. Indian J Pediatr. 2004;71(6):559-561. doi:10.1007/BF02724305

Okun MS, Jummani RR, Carney PR. Antiphospholipid- associated recurrent chorea and ballism in a child with cerebral palsy. Pediatr Neurol. 2000;23(1):62-63. doi:10.1016/s0887-8994(00)00152-1

Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi:10.1016/j.jaut.2018.05.007

Rodríguez-Pintó I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016;15(12):1120-1124. doi:10.1016/j.autrev.2016.09.010

Berman H, Rodríguez-Pintó I, Cervera R, et al. Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". Autoimmun Rev. 2014;13(2):157-162. doi:10.1016/j.autrev.2013.10.004

Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus. 1996;5(5):414-417. doi:10.1177/096120339600500516

Cabral M, Abadesso C, Conde M, Almeida H, Carreiro H. Catastrophic antiphospholipid syndrome: first signs in the neonatal period. Eur J Pediatr. 2011;170(12):1577-1583. doi:10.1007/s00431-011-1548-9

Defreitas M, Edwards-Richards A, Raj V, et al. Pediatric Catastrophic Antiphospholipid Syndrome: Case Study and Literature Review. Ann Paediatr Rheumatol2014;3(2):1DOI:10.5455/apr.051720141800

Miller DJ, Maisch SA, Perez MD, Kearney DL, Feltes TF. Fatal myocardial infarction in an 8-year-old girl with systemic lupus erythematosus, Raynaud's phenomenon, and secondary antiphospholipid antibody syndrome. J Rheumatol. 1995 ve 22(4):768-773.

Besbas N, Damarguc I, Ozen S, Aysun S, Saatci U. Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: a case report. Eur J Pediatr. 1994;153(12):891-893. doi:10.1007/BF01954739

Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217-222. doi:10.1136/annrheumdis-2011-201167

Berkun Y, Simchen MJ, Strauss T, Menashcu S, Padeh S, Kenet G. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?. Lupus. 2014;23(10):986-993. doi:10.1177/0961203314531842

Nalli C, Iodice A, Andreoli L, et al. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus. 2017;26(5):552-558. doi:10.1177/0961203317694960

Ferreira TG, Delhommeau F, Johanet C, et al. Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome. Clin Rheumatol. 2020;39(4):1167-1171. doi:10.1007/s10067-019-04915-5

Andreoli L, Nalli C, Motta M, et al. Anti-β₂-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Ann Rheum Dis. 2011;70(2):380-383. doi:10.1136/ard.2010.137281

Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. doi:10.1016/j.autrev.2014.10.019

Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019;78(2):155-161. doi:10.1136/annrheumdis-2018-213846

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-218. doi:10.1177/0961203310395803

Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14(4):358-362. doi:10.1016/j.autrev.2014.12.006

Nuri E, Taraborelli M, Andreoli L, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17-24. doi:10.1007/s12026-016-8812-z

Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560-1567.

Abisror N, Mekinian A, Lachassinne E, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;43(3):348-351. doi:10.1016/j.semarthrit.2013.07.001

Go EJL, O'Neil KM. The catastrophic antiphospholipid syndrome in children. Curr Opin Rheumatol. 2017;29(5):516-522. doi:10.1097/BOR.0000000000000426

Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213

Cervera R, Pint. IR, Espinosa G, et al. 15th International congress on antiphospholipid antibodies task force on catastrophic antiphospholipid syndrome report. In: Erkan D, Lockshin MD, eds. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017:307–316.

Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34(2):346-352.

Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12(11):1085-1090. doi:10.1016/j.autrev.2013.05.004

Nageswara Rao AA, Arteaga GM, Reed AM, Gloor JM, Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer. 2009;52(4):536-538. doi:10.1002/pbc.21878

Ruffatti A, Tarzia V, Fedrigo M, et al. Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev. 2019;18(5):561-563. doi:10.1016/j.autrev.2019.03.015

Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review. Rheumatology (Oxford). 2018;57(11):2055-2057. doi:10.1093/rheumatology/key228

Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850-855. doi:10.1002/art.22360

Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003;12(6):449-453. doi:10.1191/0961203303lu411oa